(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

Merck, known as MSD outside the United States and Canada, announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the ...

A drug for Type 2 patients, Januvia aids body in its own ability to lower blood sugar. WASHINGTON — Diabetics have gained a new way of controlling their blood sugar levels with federal approval of a ...

NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...

The savings range from 79% for Januvia, used to manage diabetes, to 38% for Imbruvica, which is used to treat blood cancers. The savings range from 79% for Januvia, used to manage diabetes, to 38% for ...

Merck stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and probably a larger ...

President Joe Biden speaks about the administration's efforts to lower prescription drug costs during an event at Prince George's Community College in Largo, Md ...

In particular, Januvia for diabetes, Isentress for HIV, and the Gardasil vaccine against human papillomavirus represent new blockbusters. All the drugs enjoyed monopoly positions at the time of launch ...

In a phase 3 trial of patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin (Invokana, Janssen Pharmaceuticals) improved glycemic control better than ...

Certain diabetes drugs can cause severe and disabling joint pain, the Food and Drug Administration warned patients on Friday. "The U.S. Food and Drug Administration (FDA) is warning that the type 2 ...

MSD, known as Merck in the United States and Canada, recently announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the ...